Platelets and vascular inflammation of the brain

Hamostaseologie

Volumn 35, Issue 3, 2015, Pages 244-251

  Mezger, M ^a   Gobel K ^b   Kraft, P ^c   Meuth, S G ^b   Kleinschnitz, C ^c   Langer, Harald ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Inflammation; Platelets

Indexed keywords

CHEMOKINE RECEPTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLYCOPROTEIN; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; IMMUNOGLOBULIN RECEPTOR; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; THROMBOCYTE RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; CYTOKINE RELEASE; DISEASE COURSE; ENDOTHELIUM CELL; HUMAN; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE MEMBRANE; ANIMAL; BIOLOGICAL MODEL; BRAIN; CEREBROVASCULAR DISEASE; ENCEPHALITIS; IMMUNOLOGY; NEUROVASCULAR COUPLING; THROMBOCYTE; VASCULITIS;

ANIMALS; BLOOD PLATELETS; BRAIN; CEREBROVASCULAR DISORDERS; ENCEPHALITIS; HUMANS; MODELS, IMMUNOLOGICAL; NEUROVASCULAR COUPLING; PLATELET ADHESIVENESS; VASCULITIS;

EID: 84939490562     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-14-11-0071     Document Type: Review

References (57)

1. Gawaz M, Geisler T. Coronary artery disease: Platelet activity: an obstacle for successful PCI. Nat Rev Cardiol 2009; 6: 391-392.
2. Von Hundelshausen P, Schmitt MM. Platelets and their chemokines in atherosclerosis-clinical applications. Front Physiol 2014; 5: 294.
3. Van Gils JM, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol 2009; 85:195-204.
4. Langer HF, Chavakis T. Platelets and neurovascular inflammation. Thromb Haemost 2013; 110:888-893.
5. Stoll G, Kleinschnitz C, Nieswandt B. Combating innate inflammation: a new paradigm for acute treatment of stroke? Ann NY Acad Sci 2010; 1207:149-154.
6. Kraft P et al. Acute ischemic stroke. New approaches to antithrombotic treatment. Nervenarzt 2012; 83: 435-449.
7. Stoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischemicstroke: novel insights and targets for treatment. Blood 2008; 112: 3555-3562.
8. Nieswandt B, Kleinschnitz C, Stoll G. Ischaemic stroke: a thrombo-inflammatory disease? J Physiol 2011; 589: 4115-4123.
9. Steinman L. Platelets provide a bounty of potential targets for therapy in multiple sclerosis. Circ Res 2012; 110: 1157-1158.
10. Gruner S et al. Multiple integrin-ligand interactions synergize in shear-resistant platelet adhesion at sites of arterial injury in vivo. Blood 2003; 102:4021-4027.
11. Inoue O et al. Integrin alpha2beta1 mediates outside- in regulation of platelet spreading on collagen through activation of Src kinases and PLCgamma2. J Cell Biol 2003; 160: 769-780.
12. Gawaz M et al. Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation 1997; 96: 1809-1818.
13. Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by plateletactivating factor. J Clin Invest 1997; 100:2085-2093.
14. Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin, and GPIbalpha. J Exp Med 1998; 187: 329-339.
15. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84:289-297.
16. Massberg S et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887-896.
17. Massberg S et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med 2003; 197: 41-49.
18. Frenette PS et al. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000; 191: 1413-1422.
19. Dole S et al. PSGL-1 regulates platelet P-selectinmediated endothelial activation and shedding of P-selectin from activated platelets. Thromb Haemost 2007; 98: 806-812.
20. Weber KS, Alon R, Klickstein LB. Sialylation of ICAM-2 on platelets impairs adhesion of leukocytes via LFA-1 and DC-SIGN. Inflammation 2004; 28: 177-188.
21. Schulz C et al. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation 2007; 116: 764-773.
22. Langer HF et al. Platelets recruit human dendritic cells via Mac-1/JAM-C interaction and modulate dendritic cell function in vitro. Arterioscler Thromb Vasc Biol 2007; 27: 1463-1470.
23. Karshovska E et al. Hyperreactivity of junctional adhesion molecule A-deficient platelets accelerates atherosclerosis in hyperlipidemic mice. Circ Res 2015; 116: 587-599.
24. Feigin VL et al. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003; 2: 43-53.
25. Yilmaz A et al. Accumulation of immune cells and high expression of chemokines/chemokine receptors in the upstream shoulder of atherosclerotic carotid plaques. Exp Mol Pathol 2007; 82:245-255.
26. Kleinschnitz C et al. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007; 115: 2323-2330.
27. Massberg S et al. Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb. Circulation 2005; 112:1180-1188.
28. Kleinschnitz C et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood 2009; 113: 3600-3603.
29. Bongers TN et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006; 37: 2672-2677.
30. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol 2004; 25: 489-95.
31. Thornton P et al. Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood 2010; 115:3632-3639.
32. Walsh PN. Platelet coagulation-protein interactions. Semin Thromb Hemost 2004; 30: 461-471.
33. Kleinschnitz C et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-518.
34. Kuijpers MJ et al. Factor XII regulates the pathological process of thrombus formation on ruptured plaques. Arterioscler Thromb Vasc Biol 2014; 34:1674-1680.
35. Bjorkqvist J, Jamsa A, Renne T. Plasma kallikrein:the bradykinin-producing enzyme. Thromb Haemost 2013; 110: 399-407.
36. Heydenreich N et al. C1-inhibitor protects from brain ischemia-reperfusion injury by combined antiinflammatory and antithrombotic mechanisms. Stroke 2012; 43: 2457-2467.
37. Muller F et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-1156.
38. Langhauser F et al. Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation. Blood 2012; 120: 4082-4092.
39. Göb E et al. Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation. Ann Neurol 2015; 77: 784-803.
40. Malgorzata P et al. Platelet reactivity in patients with stroke and hyperlipidemia, GPIbalpha assessment. Clin Appl Thromb Hemost 2014; doi:10.1177/1076029614543823.
41. Salomon O et al. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111: 4113-4117.
42. WHO. Neurological Disorders - A Public Health Approach. 2006 (cited 29.10.2014); www.who.int/ mental_health/neurology/chapter_3_a_neuro_disorders_public_h_challenges. pdf?ua=1.
43. Ffrench-Constant C. Pathogenesis of multiple sclerosis. Lancet 1994; 343: 271-275.
44. Steinman L et al. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci 2002; 25: 491-505.
45. Kihara Y et al. Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor. J Exp Med 2005; 202: 853-863.
46. Callea L et al. Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 1999; 94: 212-221.
47. Langer HF et al. Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res 2012; 110: 1202-1210.
48. Lock C et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8:500-508.
49. Kniewallner KM et al. Platelets in the Alzheimer's disease brain: do they play a role in cerebral amyloid angiopathy? Curr Neurovasc Res 2015; 12:4-14.
50. Doring A et al. E- and P-selectin are not required for the development of experimental autoimmune encephalomyelitis in C57BL/6 and SJL mice. J Immunol 2007; 179: 8470-8479.
51. Han MH et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008; 451: 1076-1081.
52. Habets KL, Huizinga TW, Toes RE. Platelets and autoimmunity. Eur J Clin Invest 2013; 43:746-757.
53. Duerschmied D et al. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood 2013; 121: 1008-1015.
54. Mostert JP et al. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a doubleblind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry 2008; 79: 1027-1031.
55. Sheremata WA et al. Evidence of platelet activation in multiple sclerosis. J Neuroinflammation 2008; 5:27.
56. Saenz-Cuesta M et al. Circulating microparticles reflect treatment effects and clinical status in multiple sclerosis. Biomark Med 2014; 8: 653-661.
57. Starossom SC et al. Glatiramer acetate (copaxone) modulates platelet activation and inhibits thrombin- induced calcium influx: possible role of copaxone in targeting platelets during autoimmune neuroinflammation. PLoS One 2014; 9: e96256.